Literature DB >> 29138023

Oleanonic acid ameliorates pressure overload-induced cardiac hypertrophy in rats: The role of PKCζ-NF-κB pathway.

Hui Gao1, Hui Liu2, Tiexin Tang2, Xiaofei Huang3, Dongxiu Wang3, Yan Li3, Pan Huang3, Yingfu Peng4.   

Abstract

It has been reported that inflammation is closely related with cardiac hypertrophy. Some inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β, and interleukin-6 directly induce cardiac hypertrophy, which is associated with the activation of nuclear factorkappa B (NF-κB). Thus, NF-κB is an attractive target for cardiac hypertrophy. In the present study, oleanonic acid inhibited the elevation of transcriptional activity of NF-κB and reduced the mRNA expressions of hypertrophic genes such as atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) in a concentration-dependent manner in phenylephrine (PE)-treated cardiomyocytes. Furthermore, we found that oleanonic acid inhibited the phosphorylation of protein kinase C ζ (PKCζ) at Thr410 site and then reduced the activation of NF-κB using gain- and loss-of-function approaches in PE-treated cardiomyocytes. In vivo, similar results were observed in abdominal aortic constriction (AAC) rats that were intragastrically administered with oleanonic acid, and the pathological changes accompanying cardiac hypertrophy were relieved. In conclusion, oleanonic acid can effectively ameliorate cardiac hypertrophy by inhibiting PKCζ-NF-κB signaling pathway.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Nuclear factor-kappa B; Oleanonic acid; Protein kinase C zeta

Mesh:

Substances:

Year:  2017        PMID: 29138023     DOI: 10.1016/j.mce.2017.11.007

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  1 in total

1.  PKC-ζ Aggravates Doxorubicin-Induced Cardiotoxicity by Inhibiting Wnt/β-Catenin Signaling.

Authors:  Yan-Jun Cao; Jing-Yan Li; Pan-Xia Wang; Zhi-Rong Lin; Wen-Jing Yu; Ji-Guo Zhang; Jing Lu; Pei-Qing Liu
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.